4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

or therapeutic medical strategies. However, the ESC Guidelines do not override in any way
whatsoever the individual responsibility of health professionals to make appropriate and …

Clinicians are encouraged to document the reasons for the use of a particular procedure or
test, whether or not it is in conformance with this statement. Clinicians also are advised to …

Background: Each of the cardiomyopathies, classically categorized as hypertrophic
cardiomyopathy, dilated cardiomyopathy (DCM), and arrhythmogenic right ventricular …

Reverse left ventricular (LV) remodeling and recovery of LV function are associated with
improved clinical outcomes in patients with heart failure with reduced ejection fraction. A …

Arrhythmogenic cardiomyopathy (ACM) is an arrhythmogenic disorder of the myocardium
not secondary to ischemic, hypertensive, or valvular heart disease. ACM incorporates a …

The ECM (extracellular matrix) network plays a crucial role in cardiac homeostasis, not only
by providing structural support, but also by facilitating force transmission, and by transducing …

Nonischemic dilated cardiomyopathy (DCM) often has a genetic pathogenesis. Because of
the large number of genes and alleles attributed to DCM, comprehensive genetic testing …

In the past decade there has been a growing interest in understanding sex and gender
differences in myocarditis and dilated cardiomyopathy (DCM), and the purpose of this review …

This guideline describes the approach and expertise needed for the genetic evaluation of
cardiomyopathy. First published in 2009 by the Heart Failure Society of America (HFSA), the …